Medtronic plc (MDT)
Investors Heavily Search Medtronic PLC (MDT): Here is What You Need to Know
Medtronic (MDT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Medtronic (MDT) Up 5.6% Since Last Earnings Report: Can It Continue?
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?
Medtronic: Strength In Cardiac Ablation Solutions, Upgrade To Buy
Upgraded Medtronic to a ‘Buy' rating with a fair value of $105 per share, driven by strong growth in Cardiac Ablation Solutions and TAVR markets. Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth, highlighting significant momentum in its Cardiac Ablation Solutions business. The company's structural heart business, especially the Evolut FX+ TAVR system, is showing strong adoption and competitive advantages over Edwards Lifesciences's SAPIEN TAVR product.
FDA classifies recall of Medtronic embolization devices as 'most serious'
The U.S. Food and Drug Administration on Tuesday classified the recall of Medtronic's embolization device as "most serious", following reports of the deaths of four patients.
Why Medtronic (MDT) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Big 3: KO, MDT, LHX
Stability is Kenny Polcari's theme when it comes to today's Big 3. He explains why Cola-Cola (KO), Medtronic (MDT) and L3Harris (LHX) are undervalued names with quality.
Positive Trial Data on Evolut TAVR Likely to Support MDT Stock
At the CRT conference 2025, Medtronic presented two-year favorable SMART trial data, which demonstrated the superior performance of the Evolut TAVR valve in patients with AS.
Medtronic explores options to optimize manufacturing operations amid Trump's tariff threats
Medical device maker Medtronic is looking at options to modify its global manufacturing footprint as part of efforts to mitigate any impact of U.S. President Donald Trump's tariff plans, a company executive told Reuters on Tuesday.
Distributor Purchasing Shifts Mar MDT's Q3 Show: How to Play the Stock
Medtronic's Medical Surgical segment faces challenges in the third quarter due to shifts in U.S. distributor buying patterns.
US FDA approves Medtronic's medical device for Parkinson's disease
The U.S. Food and Drug Administration has approved Medtronic's deep brain stimulation system for use in patients with Parkinson's disease, the medical device maker said on Monday.
Is Medtronic Stock a Buy?
Medical device manufacturer Medtronic (MDT 2.59%) is a healthcare industry stalwart. The company, based in the U.S. and Ireland, is one of the largest in its segment, developing and selling a diverse portfolio of products that includes hospital equipment and devices for cardiovascular care and diabetes.
Medtronic's Expansion Gains Momentum—Time for a Market Shift?
Medtronic's NYSE: MDT growth efforts and investments in medical technology innovation are starting to pay off. The company's pulsed field ablation (PFA) technology is a key growth driver, strengthening both its cardiac segment and overall business expansion.
